Abstract 3494
Background
An elevated pre-treatment Neutrophil to Lymphocytes Ratio (NLR) is associated with poor prognosis in various malignancies. As optimal cut-off is highly variable and few data have been reported in patients treated with anti-PD-1, we investigated the association between NLR kinetics with outcomes in patients receiving anti-PD-1.
Methods
We performed a retrospective study including successive patients with mRCC and NSCLC treated with anti PD-1 N monotherapy in second-line setting or later, between March 2013 and December 2018. NLR were prospectively collected before study entry and before every nivolumab administration. Main clinical and biological characteristics were recorded including IMDC prognostic groups for mRCC cohort. We analysed associations between baseline NLR, NLR kinetics (any increase or decrease) and survival outcomes, including PFS, OS and objective response rate (ORR).
Results
161 patients (86 mRCC and 75 NSCLC) were included in our study. With a median follow-up of 25 months, median PFS and OS were respectively 4.6 and 24.7 months for mRCC cohort and 4.4 and 16.8 months for NSCLC cohort. Between the first and the fourth N administration, 55 and 45% of the overall cohort had a decreased or an increased NLR. Survival outcomes according to NLR variations between the first and the fourth N administration are summarized in the Table. In multivariate analysis, NLR increase was associated with worse PFS (HR = 2.6; p = 0.000004) and OS (HR = 2.3; p = 0.001) for the overall cohort but also for the two cohorts when analysed separately. Association between NLR kinetics and response rate, IMDC groups and adverse events in the mRCC will be presented at the meeting.Table:
1255P Survival outcomes
All patients | |||
---|---|---|---|
NLR increase | NLR decrease | p | |
PFS (months, 95% IC) | 3.7 (2.9-4.4) | 11 (9-15.3) | <0.0001 |
OS (months, 95% CI) | 18 (10.6-28.2) | 28.5 (27;4-NR) | 0.01 |
Conclusions
We report the largest multi-cohort analysis of NLR kinetic in N treated patients supporting that early NLR increase is associated with worse survival outcomes in two distinct cohort of mRCC and NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Borchiellini: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Janssen Cilag; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Astellas. C. Thibault: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: bms; Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. P. Barthelemy: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis. Y. Vano: Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Janssen Cilag; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract